Quick Answer
GOLDENWELL BIOTECH, INC. reported Operating Income of -$123.1 thousand for fiscal year 2024.
GOLDENWELL BIOTECH, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$123.1K | -6.3% |
| 2023 | -$115.8K | +88.2% |
| 2022 | -$985.1K | -733.0% |
| 2021 | -$118.3K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.9K | +71.9% | -88.6% |
| June 30, 2025 | -$3.1K | +93.5% | +90.3% |
| March 31, 2025 | -$32.3K | -11.5% | -54.0% |
| September 30, 2024 | -$21.0K | +40.8% | +56.2% |
| June 30, 2024 | -$47.8K | -76.6% | -65.1% |
| March 31, 2024 | -$29.0K | +13.8% | +18.2% |
| September 30, 2023 | -$35.4K | -672.4% | -30.7% |
| June 30, 2023 | -$27.1K | -1.1% | +19.4% |
- GOLDENWELL BIOTECH, INC. showed a decrease of -6.3% in Operating Income compared to the prior fiscal year.
- Over the 2021–2024 period, GOLDENWELL BIOTECH, INC.’s operating income has declined by 4.1% (from -$118.3 thousand to -$123.1 thousand).
- The most recent figure is from GOLDENWELL BIOTECH, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: